

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Prasugrel hydrochloride

December 8, 2020

### **Therapeutic category**

Other agents relating to blood and body fluids

### **Non-proprietary name**

Prasugrel hydrochloride

### **Safety measure**

Precautions should be revised in the package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Revision in line with the Instructions for Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0608-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 8, 2017 (New instructions): Revised language is underlined.

Current	Revision
<p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>This drug should be co-administered with aspirin (81-100 mg/day, up to 324 mg for the initial loading dose).</p>	<p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>This drug should be co-administered with aspirin (81-100 mg/day, up to 324 mg for the initial loading dose) <u>during dual anti-platelet therapy (DAPT). The latest Japanese and overseas guidelines or other relevant sources should be referred to for the post-DAPT administration.</u></p>

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)